HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GS-CA1

archetypal small-molecule HIV capsid inhibitor; no structure available

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        GS-CA1: 3
  - Pyridines: 88
    - GS-CA1: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - GS-CA1: 3

Experts

1.	Cihlar, Tomas: 2 articles (01/2022 - 01/2019)
2.	Hansen, Derek: 2 articles (01/2022 - 01/2019)
3.	Lu, Bing: 2 articles (01/2022 - 01/2019)
4.	Yant, Stephen R: 2 articles (01/2022 - 01/2019)
5.	Zheng, Jim: 2 articles (01/2022 - 01/2019)
6.	Diaz-Griffero, Felipe: 1 article (01/2022)
7.	Hu, Pan: 1 article (01/2022)
8.	Hultquist, Judd F: 1 article (01/2022)
9.	KewalRamani, Vineet N: 1 article (01/2022)
10.	Lee, KyeongEun: 1 article (01/2022)

Related Diseases

1.

01/21/2022 - "We showed that GS-CA1 binds to the HIV-1 core, changes its conformation, stabilizes the core, and thereby prevents viral uncoating and infection."
01/21/2022 - "GS-CA1, unlike PF74, allowed the core to enter the nucleus, which agrees with the fact that GS-CA1 inhibits infection after reverse transcription. "
01/21/2022 - "We investigated the mechanism by which GS-CA1 and GS-6207 inhibit HIV-1 infection. "
01/01/2022 - "Whereas all control animals became infected after 15 weekly challenges, a single 300 mg kg-1 dose of GS-CA1 provided per-exposure infection risk reduction of 97% for 24 weeks. "
01/01/2019 - "GS-CA1 showed high antiviral efficacy as a long-acting injectable monotherapy in a humanized mouse model of HIV-1 infection, outperforming long-acting rilpivirine. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Rilpivirine (TMC-278)

Related Therapies and Procedures

1.	Injections